FIRST completes its investment in TargED for the development of Microlyse – a next-generation thrombolytic clot-busting drug
November 24th, 2020, Utrecht, the Netherlands TargED Biopharmaceuticals, a biotech spin-off of the University Medical Center Utrecht founded by Associate prof. Coen Maas, PhD, Steven de Maat, PhD, Marc van Moorsel and Kristof Vercruysse, raised EUR 1.35 million to...
NorthSea Therapeutics doses first patient in Phase 1 trial of SEFA-1024 in dyslipidemia and further expands its clinical pipeline
• NST becomes a multi-asset clinical development company, beyond NASH• Pre-clinical studies have demonstrated broad and marked beneficial effects of SEFA-1024 on non-HDL cholesterol, triglycerides, and HDL cholesterol and glycemic control• A third clinical development...
CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for checkpoint-inhibitor refractory patients
Munich, Germany, November 10, 2020 - CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the closing of its EUR50 million Series B financing round. The financing was led by Vesalius Biocapital III and joined by Novartis...
Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development
Ghent, Belgium – October 15, 2020 - Confo Therapeutics today announced the selection of its first preclinical drug candidate, CFTX-1554, a compound designed to address peripheral neuropathic pain with the potential to address additional pain indications. Confo has...
Cristal Therapeutics announces a publication in ‘Chemical Science’ on CliCr® technology platform, comprising a new class of superior copper free click reagents for conjugation of small molecules, biologics, nanoparticles and other moieties
• Flagship chemistry journal describes the development of TMTHSI (CliCr®) as a superior click reagent • Cristal applies the CliCr® platform to the rational design of CriPec® nanomedicines, also enabling modular CriVac® vaccine product development • CliCr® can be...
Synaffix wins Best Platform Technology at 7th Annual World ADC Awards
AMSTERDAM, NETHERLANDS – September 22, 2020 – Synaffix B.V., a biotechnology companyenabling antibody-drug conjugates (ADCs) with best-in-class therapeutic index, announces thatit has won the “Best ADC Platform Technology” category at the 2020 World ADC...
Scenic Biotech Enters into Genetic Modifier Collaboration with Genentech
● Multi-year strategic collaboration in target discovery and therapeutic developmentbased on Scenic Biotech’s disease modifying approach● Utilises Scenic’s unique Cell-Seq platform and its proprietary data warehouse ofgenetic modifiers● Scenic Biotech will receive an...
Synaffix Sees Competitive Early In Vivo Data from ADCs Based on Proprietary Exatecan Linker-Payload
Synaffix Announces Expansion of Collaboration with ADC Therapeutics
AMSTERDAM, NETHERLANDS – July 23, 2020 – Synaffix B.V., a biotechnology company focused on enabling antibody-drug conjugates (ADCs) with superior therapeutic index based on its proprietary ADC technology platform, announces that ADC Therapeutics SA has expanded its...
Industry veterans Paul Peter Tak and Eric Meldrum join Citryll’s Board
Oss, The Netherlands, July 21, 2020 —Citryll announced its Board has been strengthened with twoindustry veterans with impressive track-records, Businesswire Citryll. Paul Peter Tak, MD, PhD served as Professor of Medicine and Chair of the Department of...